BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

867 related articles for article (PubMed ID: 19770371)

  • 1. Primary testicular diffuse large B-cell lymphoma: a population-based study on the incidence, natural history, and survival comparison with primary nodal counterpart before and after the introduction of rituximab.
    Gundrum JD; Mathiason MA; Moore DB; Go RS
    J Clin Oncol; 2009 Nov; 27(31):5227-32. PubMed ID: 19770371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The therapeutic effect of rituximab on CD5-positive and CD5-negative diffuse large B-cell lymphoma.
    Hyo R; Tomita N; Takeuchi K; Aoshima T; Fujita A; Kuwabara H; Hashimoto C; Takemura S; Taguchi J; Sakai R; Fujita H; Fujisawa S; Ogawa K; Motomura S; Suzuki R; Ishigatsubo Y
    Hematol Oncol; 2010 Mar; 28(1):27-32. PubMed ID: 19358143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia.
    Sehn LH; Donaldson J; Chhanabhai M; Fitzgerald C; Gill K; Klasa R; MacPherson N; O'Reilly S; Spinelli JJ; Sutherland J; Wilson KS; Gascoyne RD; Connors JM
    J Clin Oncol; 2005 Aug; 23(22):5027-33. PubMed ID: 15955905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin.
    López-Guillermo A; Colomo L; Jiménez M; Bosch F; Villamor N; Arenillas L; Muntañola A; Montoto S; Giné E; Colomer D; Beà S; Campo E; Montserrat E
    J Clin Oncol; 2005 Apr; 23(12):2797-804. PubMed ID: 15728226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes and effect of radiotherapy in patients with stage I or II diffuse large B-cell lymphoma: a surveillance, epidemiology, and end results analysis.
    Ballonoff A; Rusthoven KE; Schwer A; McCammon R; Kavanagh B; Bassetti M; Newman F; Rabinovitch R
    Int J Radiat Oncol Biol Phys; 2008 Dec; 72(5):1465-71. PubMed ID: 18495371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
    Fu K; Weisenburger DD; Choi WW; Perry KD; Smith LM; Shi X; Hans CP; Greiner TC; Bierman PJ; Bociek RG; Armitage JO; Chan WC; Vose JM
    J Clin Oncol; 2008 Oct; 26(28):4587-94. PubMed ID: 18662967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diffuse large B-cell lymphoma: clinical characterization and prognosis of Waldeyer ring versus lymph node presentation.
    Qi SN; Li YX; Wang H; Wang WH; Jin J; Song YW; Wang SL; Liu YP; Zhou LQ; Yu ZH
    Cancer; 2009 Nov; 115(21):4980-9. PubMed ID: 19634158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab.
    Natkunam Y; Farinha P; Hsi ED; Hans CP; Tibshirani R; Sehn LH; Connors JM; Gratzinger D; Rosado M; Zhao S; Pohlman B; Wongchaowart N; Bast M; Avigdor A; Schiby G; Nagler A; Byrne GE; Levy R; Gascoyne RD; Lossos IS
    J Clin Oncol; 2008 Jan; 26(3):447-54. PubMed ID: 18086797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of peripheral T-cell lymphomas and diffuse large B-cell lymphoma.
    Tomita N; Motomura S; Hyo R; Takasaki H; Takemura S; Taguchi J; Fujisawa S; Ogawa K; Ishigatsubo Y; Takeuchi K
    Cancer; 2007 Mar; 109(6):1146-51. PubMed ID: 17311304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved survival for patients with large B-cell lymphoma after introduction of rituximab.
    Rodenburg EM; Maartense E; Posthuma EF
    Neth J Med; 2009 Sep; 67(8):355-8. PubMed ID: 19767667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognosis of localized diffuse large B-cell lymphoma in younger patients.
    Møller MB; Christensen BE; Pedersen NT
    Cancer; 2003 Aug; 98(3):516-21. PubMed ID: 12879468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reassessment of the prognostic factors of international prognostic index (IPI) in the patients with diffuse large B-cell lymphoma in an era of R-CHOP in Chinese population.
    Yang S; Yu Y; Jun-Min L; Jian-Qing M; Qiu-Sheng C; Yu C; Wei-Li Z; Jian-Hua Y; Hui-Jin Z; Yan W; Li W; Shu C; Zhi-Xiang S
    Ann Hematol; 2009 Sep; 88(9):863-9. PubMed ID: 19205655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sites of extranodal involvement are prognostic in patients with diffuse large B-cell lymphoma in the rituximab era: an analysis of the Surveillance, Epidemiology and End Results database.
    Castillo JJ; Winer ES; Olszewski AJ
    Am J Hematol; 2014 Mar; 89(3):310-4. PubMed ID: 24273125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study.
    Martín A; Conde E; Arnan M; Canales MA; Deben G; Sancho JM; Andreu R; Salar A; García-Sanchez P; Vázquez L; Nistal S; Requena MJ; Donato EM; González JA; León A; Ruiz C; Grande C; González-Barca E; Caballero MD;
    Haematologica; 2008 Dec; 93(12):1829-36. PubMed ID: 18945747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparative population-based analysis of sinonasal diffuse large B-cell and extranodal NK/T-cell lymphomas.
    Dubal PM; Dutta R; Vazquez A; Patel TD; Baredes S; Eloy JA
    Laryngoscope; 2015 May; 125(5):1077-83. PubMed ID: 25546466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Remission induction therapy containing rituximab markedly improved the outcome of untreated mature B cell lymphoma.
    Nagai H; Yano T; Watanabe T; Uike N; Okamura S; Hanada S; Kawano F; Sunami K; Inoue N; Sawamura M; Nishiura T; Hotta T; Horibe K
    Br J Haematol; 2008 Dec; 143(5):672-80. PubMed ID: 18950459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Presence of a high-grade component in gastric mucosa-associated lymphoid tissue (MALT) lymphoma is not associated with an adverse prognosis.
    Ang MK; Hee SW; Quek R; Yap SP; Loong S; Tan L; Tao M; Lim ST
    Ann Hematol; 2009 May; 88(5):417-24. PubMed ID: 18777110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors for poor treatment outcome and central nervous system relapse in diffuse large B-cell lymphoma with bone marrow involvement.
    Lee KW; Yi J; Choi IS; Kim JH; Bang SM; Kim DW; Im SA; Kim TY; Yoon SS; Lee JS; Bang YJ; Park S; Kim BK; Cho HI; Heo DS
    Ann Hematol; 2009 Sep; 88(9):829-38. PubMed ID: 19172274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognosis of primary thyroid lymphoma: demographic, clinical, and pathologic predictors of survival in 1,408 cases.
    Graff-Baker A; Roman SA; Thomas DC; Udelsman R; Sosa JA
    Surgery; 2009 Dec; 146(6):1105-15. PubMed ID: 19958938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary diffuse large B-cell lymphoma of the tonsil: is a higher radiotherapy dose required?
    Laskar S; Bahl G; Muckaden MA; Nair R; Gupta S; Bakshi A; Gujral S; Shet T; Shrivastava SK; Dinshaw KA
    Cancer; 2007 Aug; 110(4):816-23. PubMed ID: 17582622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.